CAS 50-22-6|Corticosterone
Introduction：Basic information about CAS 50-22-6|Corticosterone, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Corticosterone | ||
|---|---|---|---|
| CAS Number | 50-22-6 | Molecular Weight | 346.461 |
| Density | 1.2±0.1 g/cm3 | Boiling Point | 529.2±50.0 °C at 760 mmHg |
| Molecular Formula | C21H30O4 | Melting Point | 179-183 °C(lit.) |
| MSDS | ChineseUSA | Flash Point | 288.0±26.6 °C |
| Symbol | GHS07 | Signal Word | Warning |
Names
| Name | corticosterone |
|---|---|
| Synonym | More Synonyms |
Corticosterone BiologicalActivity
| Description | Corticosterone is an adrenocortical steroid that has modest but significant activities as a mineralocorticoid and a glucocorticoid. |
|---|---|
| Related Catalog | Signaling Pathways >>GPCR/G Protein >>Glucocorticoid ReceptorResearch Areas >>Neurological DiseaseNatural Products >>Steroids |
| Target | Human Endogenous Metabolite |
| References | [1]. Gasser PJ, et al. Corticosterone-sensitive monoamine transport in the rat dorsomedial hypothalamus: potential role for organiccation transporter 3 in stress-induced modulation of monoaminergic neurotransmission. J Neurosci. 2006 Aug 23;26(34):8758-8766. |
Chemical & Physical Properties
| Density | 1.2±0.1 g/cm3 |
|---|---|
| Boiling Point | 529.2±50.0 °C at 760 mmHg |
| Melting Point | 179-183 °C(lit.) |
| Molecular Formula | C21H30O4 |
| Molecular Weight | 346.461 |
| Flash Point | 288.0±26.6 °C |
| Exact Mass | 346.214417 |
| PSA | 74.60000 |
| LogP | 1.76 |
| Vapour Pressure | 0.0±3.2 mmHg at 25°C |
| Index of Refraction | 1.576 |
| InChIKey | OMFXVFTZEKFJBZ-HJTSIMOOSA-N |
| SMILES | CC12CCC(=O)C=C1CCC1C2C(O)CC2(C)C(C(=O)CO)CCC12 |
| Storage condition | Store at RT |
| Stability | Stable, but light sensitive. Incompatible with strong oxidizing agents. |
Toxicological Information
CHEMICAL IDENTIFICATION |
ACUTE TOXICITY DATA - TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intraperitoneal
- DOSE :
- 14 mg/kg
- SEX/DURATION :
- female 19-20 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Specific Developmental Abnormalities - respiratory system Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- DOSE :
- 525 mg/kg
- SEX/DURATION :
- female 12-18 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - endocrine system
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- DOSE :
- 500 mg/kg
- SEX/DURATION :
- female 8-17 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- DOSE :
- 84 mg/kg
- SEX/DURATION :
- female 16-22 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Effects on Newborn - behavioral
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intraperitoneal
- DOSE :
- 1472 mg/kg
- SEX/DURATION :
- female 11-14 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- DOSE :
- 400 mg/kg
- SEX/DURATION :
- female 11-14 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- DOSE :
- 100 mg/kg
- SEX/DURATION :
- female 13 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intramuscular
- DOSE :
- 400 mg/kg
- SEX/DURATION :
- female 11-14 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intramuscular
- DOSE :
- 40 mg/kg
- SEX/DURATION :
- female 11 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intramuscular
- DOSE :
- 80 mg/kg
- SEX/DURATION :
- female 11 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
MUTATION DATA - TYPE OF TEST :
- DNA inhibition
- TEST SYSTEM :
- Bird - chicken Embryo
- DOSE/DURATION :
- 1500 pmol/L
- REFERENCE :
- NATUAS Nature. (Nature Subscription Dept., POB 1018, Manasguan, NJ 08736) V.1- 1869- Volume(issue)/page/year: 257,804,1975
- TYPE OF TEST :
- DNA inhibition
- TEST SYSTEM :
- Bird - chicken Embryo
- DOSE/DURATION :
- 1500 pmol/L
- REFERENCE :
- NATUAS Nature. (Nature Subscription Dept., POB 1018, Manasguan, NJ 08736) V.1- 1869- Volume(issue)/page/year: 257,804,1975
Safety Information
| Symbol | GHS07 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H317 |
| Precautionary Statements | P280 |
| Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Faceshields;Gloves |
| Hazard Codes | Xi,N,Xn,T |
| Risk Phrases | R43 |
| Safety Phrases | S36 |
| RIDADR | 2811.0 |
| WGK Germany | 3 |
| RTECS | GM7650000 |
| Hazard Class | 6.1 |
Articles492
More Articles| Preventing leptin resistance by blocking angiotensin II AT1 receptors in diet-induced obese rats. Br. J. Pharmacol. 172(3) , 857-68, (2015) AT1 receptor blockers (ARBs) represent an approach for treating metabolic syndrome due to their potency in reducing hypertension, body weight and onset of type 2 diabetes. The mechanism underlying ARB... | |
| Osteopontin deletion prevents the development of obesity and hepatic steatosis via impaired adipose tissue matrix remodeling and reduced inflammation and fibrosis in adipose tissue and liver in mice. PLoS ONE 9(5) , e98398, (2014) Osteopontin (OPN) is a multifunctional extracellular matrix (ECM) protein involved in multiple physiological processes. OPN expression is dramatically increased in visceral adipose tissue in obesity a... | |
| Carotid body denervation prevents fasting hyperglycemia during chronic intermittent hypoxia. J. Appl. Physiol. 117(7) , 765-76, (2014) Obstructive sleep apnea causes chronic intermittent hypoxia (IH) and is associated with impaired glucose metabolism, but mechanisms are unknown. Carotid bodies orchestrate physiological responses to h... |
Synonyms
| Pregn-4-ene-3,20-dione, 11β,21-dihydroxy- |
| CORTICOSTERONE |
| Pregn-4-ene-3,20-dione, 11β, 21-dihydroxy- |
| Pregn-4-ene-3,20-dione, 11,21-dihydroxy-, (11β)- |
| EINECS 200-019-6 |
| 4-Pregnene-11b,21-diol-3,20-dione |
| 11b,21-Dihydroxy-4-pregnene-3,20-dione |
| MFCD00037715 |
| (11β)-11,21-Dihydroxypregn-4-ene-3,20-dione |
| Pregn-4-ene-3,20-dione, 11,21-dihydroxy-, (11-β)- (9CI) |
| 11b,21-Dihydroxyprogesterone |
| (8S,9S,10R,11S,13S,14S,17S)-11-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one |
| (11b)-11,21-Dihydroxypregn-4-ene-3,20-dione |
| 11b,21-Dihydroxypregn-4-ene-3,20-dione |
| Pregn-4-ene-3,20-dione, 11-β,21-dihydroxy- |
| 4-08-00-02907 (Beilstein Handbook Reference) |
| 4-Pregnene-11β,21-diol-3,20-dione |
